Skip to main content

Table 3 Relation of in vitro predicted susceptibility to reduction in P. aeruginosa bacterial burden at END of PEx therapies

From: Reduction in Pseudomonas aeruginosa sputum density during a cystic fibrosis pulmonary exacerbation does not predict clinical response

Factor

ALL

MUC

NON

Value

OR (95% CI)

Value

OR (95% CI)

Value

OR (95% CI)

Value

OR (95% CI)

Value

OR (95% CI)

Value

OR (95% CI)

1-log reduction

2-log reduction

1-log reduction

2-log reduction

1-log reduction

2-log reduction

All Isolates S to β-lactam vs not

59/91 vs 8/27

2.18 (CI 1.2-3.99) p = 0.002

48/91 vs 6/27

2.38 (1.14-4.94) p < 0.01

63/79 vs 10/20

1.59 (1.02-2.51), p = 0.01

48/79 vs 7/20,

1.73 (1.0-3.23) p = 0.05

55/81 vs 8/27

2.29 (1.26-4.18), p < 0.001

44/81 vs 6/27

2.44 (1.17-5.09), p = 0.004

All isolates S to TOB vs not

32/53 vs 35/65

1.12 (0.82-1.53), p = 0.56

29/55 vs 25/65

1.37 (0.92-2.03), p = 0.14

34/46 vs 39/53

1.0 (0.79-1.27), p = 1

28/46 vs 27/53

1.19 (0.84-1.69), p = 0.41

28/45 vs 35/63

1.12 (0.82-1.54), p = 0.56

25/45 vs 25/63

1.4 (0.94-2.1), p = 0.12

Regimen with 2 vs ≤1 MUC agent*

47/73 vs 12/25

1.34 (0.87-2.08), p = 0.16

39/73 vs 9/25

1.48 (0.85-2.61), p = 0.16

57/74 vs 16/25

1.2 (0.88-1.66), p = 0.29

45/74 vs 10/25

1.52 (0.91-2.54), p = 0.1

N/A

N/A

Regimen with 2 vs ≤1 NON agent*

29/41 vs 33/67

1.43 (1.05-1.96), p = 0.04

26/41 vs 24/67

1.77 (CI 1.19-2.63), p = 0.006

N/A

N/A

30/41 vs 33/67

1.49 (1.09-2.02), p = 0.02

26/41 vs 24/67

1.77 (1.19-2.63), p = 0.006

MDR at PEx* vs not

N/A

N/A

2/5 vs 59/77

0.52 (0.18-1.54), p = 0.1

1/5 vs 46/77

0.33 (0.06-1.95) p = 0.15

19/41 vs 33/47

0.66 (0.45-0.96), p = 0.03

14/41 vs 27/47

0.6 (0.36-0.97), p = 0.03

MDR in prior year* vs not

N/A

N/A

13/18 vs 47/63

0.96 (0.96-0.7-1.3), p = 1

11/18 vs 36/63

1.06 (0.7-1.63), p = 0.8

22/51 vs 30/36,

0.52 (0.36-0.73), p < 0.001

17/51 vs 24/36

0.5 (0.32-0.78), p = 0.003

PDR at PEx* vs not

N/A

N/A

0/1 vs 61/81

n/a p = 0.21

0/1 vs 46/79

n/a p = 0.4

5/13 vs 47/75

0.61 (0.3-1.29),p = 0.13

4/13 vs 37/75

0.62 (0.27-1.45), p = 0.24

PDR in prior year* vs not

N/A

N/A

0/1 vs 59/79

n/a p = 0.26

0/1 vs 46/79

n/a p = 0.43

8/22 vs 43/65

0.55 (0.31-0.98), p = 0.02

7/22 vs 34/65

0.61 (0.32-1.17), p = 0.14

  1. *In these events, bacteriologic response of P. aeruginosa was evaluated specifically against the morphotype type that susceptibility was being evaluated.
  2. S = sensitive as defined by CLSI criteria. TOB = tobramycin. MUC = mucoid isolate, NON = non-mucoid isolate. PEx = pulmonary exacerbation. OR = Odds ratio, CI = confidence interval. N/A = not applicable.
  3. MDR/PDR at event = Presence of an MDR/PDR isolate at admission sputum sample of the PEx being evaluated.
  4. MDR/PDR in prior year = Presence of an MDR/PDR isolate at any time-point in the one year prior to the PEx event being evaluated.
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us